In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover ...
As part of an educational series on qualifying biomarkers for use in drug development, the US Food and Drug Administration (FDA) has released two fictitious examples of how biomarkers can improve the ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
Digital biomarkers offer major potential, yet the pathway from research to real‑world use remains complex. TNO and Orikami are closing this gap by combining scientific validation with a certified, ...
Validated biomarkers will help physicians identify patient subgroups that will benefit most from specific treatment ...
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Objective Biomarkers and FDA-Cleared Tools While existing tools represent decades of clinical and research development, they ...
Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results